Table With No Heading/Col Selected
| Medicine | Presentation Title | Presentation Details |
| Pelacarsen | Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial | Station 12 (Research Gateway) Moderated ePoster August 29, 09:15-10:00 CEST |
| Pelacarsen | Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database | Station 2 (Research Gateway) Moderated ePoster August 30, 17:15 – 18:00 CEST |
| Pelacarsen | Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England | Discovery Pole (North Convention Centre) Poster August 29, 15:15 CEST |
| Leqvio | VICTORION-Difference study: Inclisiran-based strategy vs standard of care | Madrid (Main Auditorium) Hot Line August 30, 17:00 CEST |
| Leqvio | VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C | Discovery Pole (North Convention Centre) Poster August 29, 10:00 CEST |
| Abelacimab | Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71 | Science Box 3 (Research Gateway) Poster September 1, 14:30 CEST |
| Abelacimab | Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71 | Science Box 3 (Research Gateway) Poster September 1, 15:00 CEST |
| Entresto | PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy | Madrid (Main Auditorium) Hot Line September 1, 8:15 CEST |
| Novartis Media Relations E-mail: [email protected] |
| Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [email protected] |